ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-DLL3 Antibody-drug Conjugate FZ-AD005

Its studies are mostly in Glioblastoma · Small Cell Lung Carcinoma, led by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical.

Furthest: phase 1, since May 12, 20242 company-led studies, 2 open or runningNext primary completion: Dec 1, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical22 open or runningphase 1since May 12, 2024May 12, 2024Dec 1, 2027phase 1 · NCT07455045

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 12, 2024First study: phase 1 study in Small Cell Lung CarcinomaFirst studyNCT06424665 · 162 planned · China
  2. Mar 2, 2026Phase 1 study in GliomaNCT07455045 · 40 planned · China

Ahead

  1. Dec 1, 2027Primary completion: phase 1 study in GliomaNCT07455045

TargetBeta

DLL3 →read by rule
“An antibody-drug conjugate (ADC) composed of FZ-A038, a monoclonal antibody directed against the tumor-associated antigen (TAA) delta-like protein 3 (DLL3), ”NCIt, by rule

Other programs on DLL3

ProgramCompanyFurthest phaseStudies
tarlatamabruleAmgenphase 313
AlveltamigruleSuzhou Zelgen Biopharmaceuticalsphase 311
obrixtamigBoehringer Ingelheimphase 311
Zocilurtatug PelitecanruleZai Labphase 36
Anti-DLL3 Antibody-drug Conjugate BL-M14D1Sichuan Biokin Pharmaceuticalphase 34
gocatamigMerckphase 34
Autologous Anti-DLL3 CAR-T Cells DJI136Novartisphase 22
Anti-DLL3 Antibody-drug Conjugate IDE849ideaya-biosciencesphase 22
SHR-7787Jiangsu HengRui Medicinephase 21
clesitamigHoffmann-La Rochephase 12
Actinium Ac 225-ABD147ruleabdera-therapeutics-incphase 11
Indium In 111-ETN029Novartisphase 11

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07455045Glioma · China1Not yet recruitingDec 1, 202740
NCT06424665Small Cell Lung Carcinoma · China1RecruitingAug 1, 2026162

How it is read

Names in the registry

  • “FZ-AD005”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.